RT Journal Article
SR Electronic
T1 The relationship between Lipoprotein A and other lipids with prostate cancer risk: A multivariable Mendelian randomisation study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.01.21259705
DO 10.1101/2021.07.01.21259705
A1 Ioannidou, Anna
A1 Watts, Eleanor L
A1 Perez-Cornago, Aurora
A1 Platz, Elizabeth A
A1 Mills, Ian G
A1 Key, Timothy J
A1 Travis, Ruth C
A1 The PRACTICAL consortium, CRUK, BPC3, CAPS, PEGASUS
A1 Tsilidis, Konstantinos K
A1 Zuber, Verena
YR 2021
UL http://medrxiv.org/content/early/2021/07/05/2021.07.01.21259705.abstract
AB Background Numerous epidemiological studies have investigated the role of blood lipids in prostate cancer (PCa) risk though findings remain inconclusive to date. The ongoing research has mainly involved observational studies which are often prone to confounding. This study aimed to identify the relationship between genetically predicted blood lipid concentrations and PCa.Methods and Findings Data for low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides (TG), apolipoprotein A (apoA) and B (apoB), lipoprotein A (Lp(a)) and PCa were acquired from genome-wide association studies in UK Biobank and the PRACTICAL consortium, respectively. We used a two-sample Mendelian randomisation (MR) approach with both univariable and multivariable (MVMR) models and utilised a variety of robust methods and sensitivity analyses to assess the possibility of MR assumptions violation. No association was observed between genetically predicted concentrations of HDL, TG, apoA and apoB and PCa risk. Genetically predicted LDL concentration was positively associated with total PCa in the univariable analysis but adjustment for HDL, TG and Lp(a) led to a null association. Genetically predicted concentration of Lp(a) was associated with higher total PCa risk in the univariable (ORweighted median per sd = 1.091; 95% CI 1.028-1.157; P=0.004) and MVMR analyses after adjustment for the other lipid traits (ORIVW per sd = 1.068; 95% CI 1.005-1.134; P = 0.034). Genetically predicted Lp(a) was also associated with advanced (MVMR ORIVW per sd = 1.078; 95% CI 0.999-1.163; P=0.055) and early age onset PCa (MVMR ORIVW per sd = 1.150; 95% CI 1.015,1.303; P = 0.028). Although multiple estimation methods were utilized to minimize the effect of pleiotropic traits, the presence of any unmeasured pleiotropy cannot be excluded and may limit our findings.Conclusions We observed that genetically predicted Lp(a) concentrations are associated with an increased PCa risk. Future studies are required to understand the underlying biological pathways of this finding, as it may inform PCa prevention through Lp(a)-lowering strategies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementKKT was supported by Cancer Research UK (C18281/A29019). ELW was supported by the NDPH Early Career Research Fellowship. APC is supported by a Cancer Research UK Population Research Fellowship (C60192/A28516) and by the World Cancer Research Fund (WCRF UK), as part of the Word Cancer Research Fund International grant programme (2019/1953).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study is based on existing summary-level data by i) UK Biobank and ii) the PRACTICAL consortium and no individual-level data has been collected or analysed. i) UK Biobank has ethical approval from the North West Multi-centre Research Ethics Committee (MREC). ii) All studies contributing to the PRACTICAL consortium were approved by the appropriate ethics committees (as described in the references for each study listed in Supplementary Table 1 of Schumacher, Al Olama, Berndt, et al. 2018 (https://doi.org/10.1038/s41588-018-0142-8)), and informed consent was obtained from all participants. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSummary-level data on genetic associations with blood lipids in men (http://www.nealelab.is/uk-biobank) and overall prostate cancer (http://practical.icr.ac.uk/) are in the public domain. Summary-level data on genetic associations with subtypes of prostate cancer are available from the Practical Consortium. http://www.nealelab.is/uk-biobank http://practical.icr.ac.uk/